SAN

101.08

+2.18%↑

EI

256

-3.51%↓

SHL.DE

48.16

-2.77%↓

ARGX

545

+3.69%↑

FRE

39.72

+2.8%↑

SAN

101.08

+2.18%↑

EI

256

-3.51%↓

SHL.DE

48.16

-2.77%↓

ARGX

545

+3.69%↑

FRE

39.72

+2.8%↑

SAN

101.08

+2.18%↑

EI

256

-3.51%↓

SHL.DE

48.16

-2.77%↓

ARGX

545

+3.69%↑

FRE

39.72

+2.8%↑

SAN

101.08

+2.18%↑

EI

256

-3.51%↓

SHL.DE

48.16

-2.77%↓

ARGX

545

+3.69%↑

FRE

39.72

+2.8%↑

SAN

101.08

+2.18%↑

EI

256

-3.51%↓

SHL.DE

48.16

-2.77%↓

ARGX

545

+3.69%↑

FRE

39.72

+2.8%↑

Search

Valneva SE

Ouvert

3.2 -0.62

Résumé

Variation du prix de l'action

24h

Actuel

Min

3.09

Max

3.25

Chiffres clés

By Trading Economics

Revenu

-28M

-37M

Ventes

7.1M

53M

BPA

-0.25

Marge bénéficiaire

-69.865

Employés

713

EBITDA

-19M

-26M

Recommandations

By TipRanks

Recommandations

Achat

Prévisions sur 12 Mois

+78.13% upside

Dividendes

By Dow Jones

Prochains Résultats

7 mai 2025

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

-64M

513M

Ouverture précédente

3.82

Clôture précédente

3.2

Score Technique

By Trading Central

Confiance

Weak Bullish Evidence

Valneva SE Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

15 nov. 2024, 10:28 UTC

Principaux Mouvements du Marché

European Vaccine Makers Under Pressure After Trump Picks RFK Jr to Lead Health Department

3 sept. 2024, 10:28 UTC

Résultats

Pfizer, Valneva Report Positive Lyme Disease Vaccine Candidate Data

15 nov. 2024, 10:34 UTC

Market Talk

Vaccine Sector Sell-Off Looks Overdone -- Market Talk

3 sept. 2024, 10:31 UTC

Market Talk

Valneva Shares Gain on Positive Vaccine News -- Market Talk

Comparaison

Variation de prix

Valneva SE prévision

Objectif de Prix

By TipRanks

78.13% hausse

Prévisions sur 12 Mois

Moyen 5.7 EUR  78.13%

Haut 8.1 EUR

Bas 3.3 EUR

Basé sur 2 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

2 ratings

1

Achat

1

Maintien

0

Vente

Score Technique

By Trading Central

3.2 / 3.32Support & Résistance

Court Terme

Weak Bullish Evidence

Moyen Terme

Strong Bullish Evidence

Long Terme

Strong Bullish Evidence

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Valneva SE

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine. The company also develops VLA15, a vaccine candidate, which is in Phase III clinical trial against Borrelia, the bacterium that causes Lyme disease; VLA1553, a vaccine candidate, which is in Phase III clinical trial against the chikungunya virus; VLA1554, a vaccine candidate targeting human metapneumovirus; and VLA2112, a vaccine candidate to treat patients with epstein-barr virus. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, France, rest of European countries, and internationally. Valneva SE has collaborations with Pfizer, Inc. to co-develop and commercialize its Lyme disease vaccine; and Instituto Butantan for the development, manufacturing, and marketing of single-shot chikungunya vaccine. The company was founded in 1998 and is based in Saint-Herblain, France.